Sequenom makes hostile offer for Exact Sciences
By
Associated Press
January 14, 2009
|
Genetic analysis product maker Sequenom Inc. offered a hostile bid for colon cancer test developer Exact Sciences Inc. Wednesday, two days after the board of Exact Sciences rejected a buyout offer from Sequenom.
Sequenom offered to buy Cambridge, Mass.-based Exact Sciences on Friday for $41 million, or $1.50 per share, hoping to gain the company's intellectual property and use it to develop cancer diagnostic products. The board of Exact Sciences said it is pursuing another, more valuable option.
San Diego-based Sequenom did not change the terms of its all-stock offer, but is now making its pitch directly to shareholders.
Shares of Exact Sciences rose 7 cents to $1.57 Tuesday, suggesting investors may expect an increased offer. Sequenom stock finished at $23.74.